NeuroHope Therapeutics, Inc.
NeuroHope Therapeutics, Inc.
Offering Hope to Those in Need
Mission Statement
To develop polymeric nanoparticle drug delivery systems that improve motor and cognitive functional recovery and quality of life for patients suffering neurotrauma or neurodegenerative diseases.
Business Profile
NeuroHope Therapeutics, Inc. is a South Carolina-based start-up seeking to develop and commercialize micellar nanotherapeutics for local, sustained drug delivery to treat central nervous system trauma such as spinal cord injury or traumatic brain injury.
Our proprietary polymeric carrier, PgP, increases drug solubility and provides prolonged residence time and sustained drug release at the site of local injection. Our lead candidate is composed of PgP loaded with the phosphodiesterase IV inhibitor, rolipram (Rm-PgP). In rat preclinical contusion spinal cord injury models, Rm-PgP has been shown to preserve / restore cyclic AMP levels; reduce neuroinflammation, apoptosis, and astrogliosis; and significantly improve motor functional recovery.
Our proprietary polymeric carrier, PgP, increases drug solubility and provides prolonged residence time and sustained drug release at the site of local injection. Our lead candidate is composed of PgP loaded with the phosphodiesterase IV inhibitor, rolipram (Rm-PgP). In rat preclinical contusion spinal cord injury models, Rm-PgP has been shown to preserve / restore cyclic AMP levels; reduce neuroinflammation, apoptosis, and astrogliosis; and significantly improve motor functional recovery.